eligibility_summary
Eligible: adults ≥18 with R/R MM after ≥3 prior lines incl PI and IMiD (RRpPCL ≥1 line), progressive, measurable disease, ECOG 0–1, survival >12 wks, consent and LTFU 15 yrs, contraception. Exclude: pregnant, active HIV/HBV/HCV or infections, unresolved AEs >G1, prior allo-SCT or recent auto-SCT, recent therapy/steroids/vaccines, allergy to study meds, WM/POEMS/AL, cardiac disease, O2-dependent or severe COPD, autoimmune disease, recent other cancers, CNS disease, recent/planned major surgery.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Intervention: CT0596 CAR-T cell injection (autologous, gene-modified cellular immunotherapy). Mechanism: patient T cells are engineered ex vivo to express a chimeric antigen receptor that binds a plasma cell surface antigen (target not specified in the listing), driving MHC-independent recognition, T-cell activation/expansion, cytokine release, and perforin/granzyme-mediated cytotoxicity against tumor cells. Targets: malignant plasma cells in relapsed/refractory multiple myeloma and plasma cell leukemia, key pathways include CAR signaling in T cells and downstream immune effector cytotoxic pathways.